FLINT, Mich. — Diplomat Pharmacy’s board of directors has appointed Dave Loschinskey to serve as chief operating officer effective May 2.  In addition, Gary Rice will retire from his position as executive vice president of operations effective May 17.

Brian Griffin

Brian Griffin, Diplomat’s chairman and chief executive officer expressed his gratitude to Gary Rice: “I want to thank Gary for his significant contributions to Diplomat in his 8 years at the company.  Gary has been instrumental in the company’s growth during his tenure and we wish him all the best in his future endeavors.”

Prior to being appointed to chief operating officer, Loschinskey served as Diplomat’s chief information officer.  In his new role Loschinskey will report to Brian Griffin, and will manage the company’s operations.  He will drive innovative digital and data-driven service offerings to improve clinical care and reduce total healthcare costs for payers looking for an independent alternative in the marketplace. At the same time, he is committed to operational excellence and will work with the entire Diplomat team to improve operational efficiency and ensure the highest quality patient care.

“Dave is a seasoned executive with experience in a variety of operations and IT roles, including more than 15 years in the specialty pharmacy industry.  Dave has a rare ability to optimize and re-engineer operations, while engaging our client’s patients through technology, which will serve us well as we continue to adapt in this changing marketplace,” said Griffin.

“Since joining Diplomat in 2017, I have worked closely with the entire Diplomat team to measure and improve the patient experience through technology and innovation,” said Loschinskey. “I look forward to working even closer with our leadership team to improve operational efficiency and execute the company’s strategy to create lasting value for patients and for our payer, physician and manufacturer partners, as well as our shareholders.  Diplomat’s storied past as a clinical leader and the largest independent specialty pharmacy and infusion provider will continue to serve as our guidepost for future innovation and modernized patient engagement.”